Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJB3E1)

• Drug Name: VITAMIN K2 Drug Info
• Synonyms: menaquinone-2; MK-2; menaquinone(2); AC1NQWYQ; Prestwick3_001100; BSPBio_001180; SCHEMBL416517; 2-(3,7-dimethylocta-2,6-dienyl)-3-methylnaphthalene-1,4-dione; CHEMBL263382; BPBio1_001298; GTPL2771; PTWSIIUEOFZCHW-NTCAYCPXSA-N; HMS2098K22; 2-(3,7-Dimethyl-2,6-octadienyl)-3-methyl-1,4-naphthoquinone; 1,4-Naphthoquinone, 2-(3,7-dimethyl-2,6-octadienyl)-3-methyl-; ZINC1532757; AKOS015899893; CJ-24250; 1163-13-9; 7421-23-0; AB00514047; C00828; I14-11159; 2-Methyl-3-(3,7-dimethyl-2,6-octadienyl)-1,4-naphthoquinone

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5282367
  ChEBI ID: CHEBI:78277
  CAS Number: CAS 863-61-6
  TTD Drug ID: DMJB3E1

Molecule-Related Drug Atlas

Drug(s) Targeting Trypanosoma Cruzipain (Trypano CYSP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TRICLABENDAZOLE	DMPWGBR	Helminth infection	1F90.0	Approved	[2]
MANIDIPINE	DMJPGUA	N. A.	N. A.	Phase 3	[2]
L-755507	DMPWBNU	N. A.	N. A.	Terminated	[5]
GNF-PF-4478	DMCDU8K	Discovery agent	N.A.	Investigative	[6]
K-777	DMIFCMW	Discovery agent	N.A.	Investigative	[7]
WRR-99	DM8ZA6K	Discovery agent	N.A.	Investigative	[8]
Benzoyl-Arginine-Alanine-Methyl Ketone	DMC7TNF	Discovery agent	N.A.	Investigative	[8]
Vinylsulphones	DMNFVO7	Infection of P. falciparum	1F40	Investigative	[9]
WRR-112	DMP761U	Discovery agent	N.A.	Investigative	[8]
1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione	DM30M9H	Discovery agent	N.A.	Investigative	[10]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[11]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[11]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[12]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[13]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[14]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[11]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[11]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[11]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[15]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[16]

Drug(s) Affected By Bone morphogenetic protein 2 (BMP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[17]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[19]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[21]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[22]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[24]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[26]

Drug(s) Affected By Cytochrome P450 4F2 (CYP4F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Warfarin	DMJYCVW	Atrial fibrillation	BC81.3	Approved	[27]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[28]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[29]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[30]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[26]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[32]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[28]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[33]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Trypanosoma Cruzipain (Trypano CYSP)	TTEAID7	CYSP_TRYCR	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Bone morphogenetic protein 2 (BMP2)	OT23T37S	BMP2_HUMAN	Gene/Protein Processing	[3]
Cytochrome P450 4F2 (CYP4F2)	OTKILAER	CP4F2_HUMAN	Regulation of Drug Effects	[4]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2771).
• [2] Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65.
• [3] Menaquinone-4 Accelerates Calcification of Human Aortic Valve Interstitial Cells in High-Phosphate Medium through PXR. J Pharmacol Exp Ther. 2020 Mar;372(3):277-284. doi: 10.1124/jpet.119.263160. Epub 2019 Dec 16.
• [4] Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. Thromb Res. 2015 May;135(5):861-6. doi: 10.1016/j.thromres.2015.02.019. Epub 2015 Feb 27.
• [5] Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51.
• [6] Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem. 2010 Jul 8;53(13):4891-905.
• [7] Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6218-21.
• [8] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [9] Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
• [10] Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3527-30.
• [11] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [12] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [13] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [14] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [15] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [16] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [17] Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol. 2010 Feb;37(2):246-56. doi: 10.3899/jrheum.090167. Epub 2009 Dec 15.
• [18] Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 2000 May 19;271(3):688-92. doi: 10.1006/bbrc.2000.2697.
• [19] Quercetin, a flavonoid, inhibits proliferation and increases osteogenic differentiation in human adipose stromal cells. Biochem Pharmacol. 2006 Nov 15;72(10):1268-78. doi: 10.1016/j.bcp.2006.08.021. Epub 2006 Sep 22.
• [20] Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. 2007 Mar;34(3):310-23. doi: 10.1016/j.mcn.2006.11.008. Epub 2006 Dec 28.
• [21] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [22] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [23] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [24] Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem. 2007 Aug 15;101(6):1430-8. doi: 10.1002/jcb.21259.
• [25] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [26] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [27] CYP4F2 genetic variant alters required warfarin dose. Blood. 2008 Apr 15;111(8):4106-12. doi: 10.1182/blood-2007-11-122010. Epub 2008 Feb 4.
• [28] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [29] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [30] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [31] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [32] CYP4F2 repression and a modified alpha-tocopherol (vitamin E) metabolism are two independent consequences of ethanol toxicity in human hepatocytes. Toxicol In Vitro. 2017 Apr;40:124-133.
• [33] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.